IDH-Wildtype Glioblastoma, WHO Grade 4
This molecular profile is most consistent with an IDH-wildtype glioblastoma (WHO grade 4), representing the most common and aggressive primary brain tumor in adults. 1
Molecular Reasoning
The key diagnostic features pointing to IDH-wildtype glioblastoma include:
Defining Characteristics Present:
- Wild-type IDH1/IDH2: The absence of IDH mutations is the primary distinguishing feature that separates this from lower-grade astrocytomas and oligodendrogliomas 1
- TP53 mutation: Present in approximately 25-30% of IDH-wildtype glioblastomas, though more commonly associated with IDH-mutant astrocytomas 2, 3
- PIK3CA amplification: Occurs in IDH-wildtype glioblastomas as part of the receptor tyrosine kinase/PI3K/AKT pathway dysregulation 2
Key Exclusions:
- No EGFR amplification: While EGFR amplification occurs in 40-50% of IDH-wildtype glioblastomas, its absence does not exclude the diagnosis 1
- No CDKN2A deletion: Homozygous CDKN2A/B deletion is a marker of WHO grade 4 but is not required for diagnosis 1
- No BRAF mutation: Excludes BRAF-driven low-grade gliomas and glioneuronal tumors 1
Diagnostic Algorithm
According to EANO guidelines, IDH-wildtype glioblastomas are classified based on:
Histological features: Presence of necrosis and/or microvascular proliferation automatically qualifies as WHO grade 4 1
In the absence of these histological features, evaluate for glioblastoma-associated molecular alterations:
- EGFR amplification
- TERT promoter mutations
- +7/-10 cytogenetic signature
If one or more of these alterations is present, classify as IDH-wildtype glioblastoma even without necrosis or microvascular proliferation 1
Important Caveats
The TP53 + PIK3CA Pattern:
This combination is somewhat atypical for classic IDH-wildtype glioblastoma. Research shows that among glioblastomas with TP53 mutations, 52% have concurrent mutations in actionable genes, with PIK3CA mutations occurring in approximately 4-11% 2. This molecular signature may represent:
- A less common molecular subtype of IDH-wildtype glioblastoma
- Potentially younger patient age at presentation 1
- Possible alternative telomere maintenance mechanism given the absence of TERT promoter mutation (if tested) 4
Critical Additional Testing Needed:
To complete the molecular diagnosis, you should evaluate:
- TERT promoter mutation status: Present in ~70% of IDH-wildtype glioblastomas and is a molecular marker of WHO grade 4 1
- +7/-10 cytogenetic signature: Gain of chromosome 7 with loss of chromosome 10 is a defining molecular marker 1
- Histological grade: Presence of necrosis or microvascular proliferation
- ATRX status: Loss would be unusual in IDH-wildtype tumors and might suggest reconsideration of IDH testing 1
Differential Considerations:
If this tumor lacks the typical glioblastoma-associated alterations (EGFR amplification, TERT promoter mutation, +7/-10 signature) and shows no necrosis or microvascular proliferation, it may represent an IDH-wildtype diffuse astrocytoma requiring further molecular assessment, particularly in younger patients 1. However, the presence of TP53 mutation with PIK3CA amplification in an adult patient still favors IDH-wildtype glioblastoma.
Clinical Implications:
The absence of EGFR amplification and presence of PIK3CA alterations may have therapeutic relevance for clinical trial eligibility targeting the PI3K/AKT/mTOR pathway 5. The TP53 mutation may confer resistance to certain therapies and is associated with poorer outcomes even within IDH-wildtype glioblastomas 6.